Clinical Trials

260 enrolled

Stomach Neoplasms

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

100 enrolled

Melanoma

NCT06345183 2025-11-06

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

327 enrolled

Genitourinary

Advanced Renal Cell Carcinoma (aRCC)

NCT03963518 2025-10-06

SURROGATE-ICI

631 enrolled 6 charts

Tumor-Agnostic

Neoplasms

NCT06771674 2025-09-09

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

662 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

291 enrolled

Stomach Neoplasms

NCT04050761 2025-07-02

ProNiHN

502 enrolled

Head & Neck

Head and Neck Neoplasms

NCT06499298 2025-05-31

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

64 enrolled

Esophageal Neoplasms

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04146324 2025-01-24

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

150 enrolled

Melanoma

NCT06735781 2024-12-16

Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

101 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06361563 2024-04-12

Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

250 enrolled

Gastrointestinal Neoplasms

NCT06361576 2024-04-12

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

700 enrolled

Gastrointestinal Neoplasms

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

600 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT05611229 2023-04-06

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

1,975 enrolled

Melanoma

NCT03453892 2023-02-16

ST-ICI

150 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04936399 2022-05-25

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT05068609 2022-05-05

VOLUME-PRO

509 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03486119 2020-10-19

A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03132493 2018-11-14

NIVEX

676 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03165409 2017-10-05

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

1,828 enrolled